Navigation Links
KemPharm, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
Date:8/6/2014

CORALVILLE, Iowa, Aug. 6, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that President and CEO, Travis Mickle, Ph.D., will present at the Canaccord Genuity 34th Annual Growth Conference at the InterContinental Boston Hotel in Boston, MA.

Among the topics to be discussed, Dr. Mickle will provide an overview of KemPharm's clinical, regulatory and commercial strategy for KP201, the company's lead clinical candidate for the treatment of acute moderate to moderately severe pain.  Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). 

Details of KemPharm's presentation are as follows: Event:Canaccord Genuity 34th Annual Growth ConferenceDate: August 13, 2014Time: 11:00 a.m. – 11:25 a.m. ETLocation:InterContinental Boston HotelAbout KemPharmKemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  For more information on KemPharm, please visit the company's website at www.kempharm.com.For KemPharm, Inc:Media / Investor Contacts:Gordon K. "Rusty" Johnson

319-665-2575

info@kempharm.com

Jason Rando / Joshua Drumm, Ph.D.

Tiberend Strategic Advisors, Inc.

212.375.2665 / 2664

jrando@tiberend.com

jdrumm@tiberend.com


'/>"/>
SOURCE KemPharm, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
2. MEI Pharma To Present At Wedbush PacGrow Life Sciences And Canaccord Genuity Growth Conferences
3. Cynosure to Present at Canaccord Genuity 34th Annual Growth Conference
4. IRIDEX to Present at 2014 Wedbush Life Sciences Management Access Conference
5. HeartWare Presentation At The Canaccord Genuity 34th Annual Growth Conference To Be Webcast
6. CryoLife to Present at 34th Annual Canaccord Genuity Growth Conference
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference
9. Cardica To Present At 2014 Wedbush PacGrow Life Sciences Management Access Conference
10. Thoratec Presentation At Canaccord Genuity Growth Conference To Be Webcast
11. Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
(Date:5/27/2016)... 27, 2016 Kitov ... focused on late-stage drug development, today announced the ... of pivotal batches required for registration of KIT-302 ... This follows Kitov,s announcement in December ... met its primary efficacy endpoint. "We ...
(Date:5/27/2016)... The healthcare sector is large ... all falling under its umbrella.  A rather overlooked sector ... talked about, these healthcare companies are still trying to ... is by far the largest consumer of the healthcare ... ADMD), Nutranomics Inc. (OTC: NNRX), KollagenX Corp. (OTCQB: KGNX), ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... , ... Psoriasis: Targets and Therapy has published ... author Professor Luigi Naldi says “The review in Psoriasis: Targets and Therapy throws ... onset and the severity of psoriasis, and negatively influences the response to systemic ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... individuals’ genetic characteristics and the physical and behavioral worlds in which they ... In personalized medicine, diagnosing an individual’s disease depends on accurately assessing his ...
(Date:5/31/2016)... ... May 31, 2016 , ... More than 80 representatives of the ... and the Prevent Cancer Foundation held an event on National Hepatitis Testing Day outside ... of viral hepatitis, the leading cause of liver cancer. , Foundation leaders and the ...
(Date:5/31/2016)... ... May 31, 2016 , ... Splashtop Inc., the worldwide leader in high ... Co., the leading provider of secure mobile remote access solution for Japan enterprises. ... CACHATTO remote access solution. Splashtop for CACHATTO will be available as an ...
(Date:5/31/2016)... ... ... Twenty years ago it was revolutionary: enabling the people who hear distressing voices to ... this approach has proven transformative, both for people who hear voices and for the ... used around the world, but it still lags in the United States. , Now, ...
Breaking Medicine News(10 mins):